Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3181
-$0.0359-10.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 3.14M | 2.98M | 6.00M | 2.80M | 3.38M |
| Total Receivables | -- | 1.25M | 974.00K | 1.34M | 2.93M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 237.00K | 374.00K | 433.00K | 329.00K | 792.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 300.00K | 309.00K | 300.00K | 365.00K | 341.00K |
| Total Current Assets | 3.67M | 4.91M | 7.71M | 4.84M | 7.44M |
|
|
|||||
| Total Current Assets | 3.67M | 4.91M | 7.71M | 4.84M | 7.44M |
| Net Property, Plant & Equipment | 8.00K | 55.00K | 70.00K | 86.00K | 102.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 412.00K | 413.00K | 413.00K | 1.24M | 1.26M |
| Total Assets | 4.09M | 5.38M | 8.19M | 6.17M | 8.81M |
|
|
|||||
| Total Accounts Payable | 4.60M | 4.13M | 4.74M | 5.20M | 3.54M |
| Total Accrued Expenses | 1.39M | 1.89M | 2.05M | 2.85M | 4.24M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | 283.00K | 332.00K | 395.00K | 296.00K | 380.00K |
| Total Other Current Liabilities | 283.00K | 332.00K | 395.00K | 296.00K | 380.00K |
| Total Current Liabilities | 6.27M | 6.35M | 7.19M | 8.35M | 8.16M |
|
|
|||||
| Total Current Liabilities | 6.27M | 6.35M | 7.19M | 8.35M | 8.16M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | 5.00K | 21.00K | 37.00K |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 6.27M | 6.35M | 7.19M | 8.37M | 8.20M |
|
|
|||||
| Common Stock & APIC | 438.21M | 436.51M | 436.40M | 429.92M | 429.80M |
| Retained Earnings | -439.49M | -436.44M | -434.49M | -431.23M | -428.28M |
| Treasury Stock & Other | -891.00K | -1.03M | -915.00K | -898.00K | -908.00K |
| Total Common Equity | -2.17M | -970.00K | 999.00K | -2.21M | 607.00K |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -2.17M | -970.00K | 999.00K | -2.21M | 607.00K |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -2.17M | -970.00K | 999.00K | -2.21M | 607.00K |
|
|
|||||